. 2022 Dec 10;12(12):3118. doi: 10.3390/diagnostics12123118

Table 1.

Research questions.

Research Questions
Did the number of patients diagnosed with AP decrease during the COVID-19 pandemic, and what would the explanation for this be? Did the mean values of the already known inflammatory markers NLR, PLR, MLR, dNLR, AISI, SIRI, and SII and the newly introduced MCVL and IIC change during the COVID-19 period? Were there any differences in terms of the number of complications with surgical risk and their degree of operability during the COVID-19 period? Among the already known inflammatory markers NLR, PLR, MLR, dNLR, AISI, SIRI, and SII and the newly introduced MCVL and IIC, which of them can effectively predict the complications with the surgical risk (abscess, necrosis, and pseudocyst) and mortality in the pre-COVID and peri-COVID periods?

Research Questions

Did the number of patients diagnosed with AP decrease during the COVID-19 pandemic, and what would the explanation for this be?
Did the mean values of the already known inflammatory markers NLR, PLR, MLR, dNLR, AISI, SIRI, and SII and the newly introduced MCVL and IIC change during the COVID-19 period?
Were there any differences in terms of the number of complications with surgical risk and their degree of operability during the COVID-19 period?
Among the already known inflammatory markers NLR, PLR, MLR, dNLR, AISI, SIRI, and SII and the newly introduced MCVL and IIC, which of them can effectively predict the complications with the surgical risk (abscess, necrosis, and pseudocyst) and mortality in the pre-COVID and peri-COVID periods?